Stem cell-derived retinal cells need primary cilia to support survival of light-sensing photoreceptors
Scientists at the National Eye Institute (NEI), part of the National Institutes of Health, report that tiny tube-like protrusions called primary cilia on cells of the retinal pigment epithelium (RPE)—a layer of cells in the back of the eye—are essential for the survival of the retina’s light-sensing photoreceptors. The discovery has advanced efforts to make stem cell-derived RPE for transplantation into patients with geographic atrophy, otherwise known as dry age-related macular degeneration (AMD), a leading cause of blindness in the U.S. The study appears in the January 2 Cell Reports.
“We now have a better idea about how to generate and replace RPE cells, which appear to be among the first type of cells to stop working properly in AMD,” said the study’s lead investigator, Kapil Bharti, Ph.D., Stadtman investigator at the NEI. Bharti is leading the development of patient stem cell-derived RPE for an AMD clinical trial set to launch in 2018.
In a healthy eye, RPE cells nourish and support photoreceptors, the cells that convert light into electrical signals that travel to the brain via the optic nerve. RPE cells form a layer just behind the photoreceptors. In geographic atrophy, RPE cells die, which causes photoreceptors to degenerate, leading to vision loss.
Bharti and his colleagues are hoping to halt and reverse the progression of geographic atrophy by replacing diseased RPE with lab-made RPE. The approach involves using a patient’s blood cells to generate induced-pluripotent stem cells (iPSCs), cells capable of becoming any type of cell in the body. iPSCs are grown in the laboratory and then coaxed into becoming RPE for surgical implantation.
Attempts to create functional RPE implants, however, have hit a recurring obstacle: iPSCs programmed to become RPE cells have a tendency to get developmentally stuck, said Bharti. “The cells frequently fail to mature into functional RPE capable of supporting photoreceptors. In cases where they do mature, however, RPE maturation coincides with the emergence of primary cilia on the iPSC-RPE cells.”
The researchers tested three drugs known to modulate the growth of primary cilia on iPSC-derived RPE. As predicted, the two drugs known to enhance cilia growth significantly improved the structural and functional maturation of the iPSC-derived RPE. One important characteristic of maturity observed was that the RPE cells all oriented properly, correctly forming a single, functional monolayer. The iPSC-derived RPE cell gene expression profile also resembled that of adult RPE cells. And importantly, the cells performed a crucial function of mature RPE cells: they engulfed the tips of photoreceptor outer segments, a pruning process that keeps photoreceptors working properly.
By contrast, iPSC-derived RPE cells exposed to the third drug, an inhibitor of cilia growth, demonstrated severely disrupted structure and functionality.
As further confirmation of their observations, when the researchers genetically knocked down expression of cilia protein IFT88, the iPSC-derived RPE showed severe maturation and functional defects, as confirmed by gene expression analysis. Tissue staining showed that knocking down IFT88 led to reduced iPSC-derived RPE cell density and functional polarity, i.e., cells within the RPE tissue pointed in the wrong direction.
Bharti and his group found similar results in iPSC-derived lung cells, another type of epithelial cell with primary cilia. When iPSC-derived lung cells were exposed to drugs that enhance cilia growth, immunostaining confirmed that the cells looked structurally mature.
The report suggests that primary cilia regulate the suppression of the canonical WNT pathway, a cell signaling pathway involved in embryonic development. Suppression of the WNT pathway during RPE development instructs the cells to stop dividing and to begin differentiating into adult RPE, according to the researchers.
The researchers also generated iPSC-derived RPE from a patient with ciliopathy, a disorder that causes severe vision loss due to photoreceptor degeneration. The patient’s ciliopathy was associated with mutations of cilia gene CEP290. Compared to a healthy donor, iPSC-derived RPE from the ciliopathy patient had cilia that were smaller. The patient’s iPSC-derived RPE also had maturation and functional defects similar to those with IFT88 knockdown.
Further studies in a mouse model of ciliopathy confirmed an important temporal relationship: Looking across several early development stages, the RPE defects preceded the photoreceptor degeneration, which provides additional insights into ciliopathy-induced retinal degeneration.
The Latest on: Dry age-related macular degeneration
- From cataracts to macular degeneration: Age-related eye problems and how to treat themon November 14, 2019 at 6:23 am
This is particularly the case for Monique, who also has the onset of age-related macular degeneration (AMD ... coloring (pigment reworking), a phenomenon that is also visible when the retina is ...
- Age-related macular degeneration Industry – Treatment, Outlook, Analysis, Research, Review to 2023on November 12, 2019 at 3:09 am
Age-Related Macular Degeneration (AMD) is a condition that affects the back of the eye called the macula. AMD is described as either dry or wet AMD. Age-related macular degeneration causes progressive ...
- Lack of awareness and treatment delays put people with wet macular degeneration at risk of avoidable sight losson November 5, 2019 at 6:21 am
The findings come from 'Patient-reported reasons for delay in diagnosis of age-related macular degeneration: a national survey', a paper by Alice Parfitt ... The sooner the treatment is given, the ...
- Age-Related Macular Degeneration Market visualized increasing with 7.8 % CAGR and reach around USD 11,186.8 Million between 2019 and 2023on October 28, 2019 at 2:28 am
Age-related macular degeneration (AMD) is a chronic irreversible medical condition that results in central vision loss because of damage to the central area of the retina (macula). This condition is ...
- Study pinpoints cell types linked to age-related macular degenerationon October 25, 2019 at 6:35 am
Age-related macular degeneration is one of the leading causes of blindness ... Other than eye vitamin supplements, there is no treatment for the dry form of the disease, which is marked by ...
- Single-cell transcriptomic atlas of the human retina identifies cell types associated with age-related macular degenerationon October 25, 2019 at 2:17 am
Genome-wide association studies (GWAS) have identified genetic variants associated with age-related macular degeneration (AMD), one of the leading causes of blindness ... The remaining tissue was snap ...
- Trial drug improves vision in age-related macular degenerationon October 15, 2019 at 5:11 pm
Patients with “dry” age-related macular degeneration have shown dramatic eyesight improvements in a small phase 2 clinical drug trial. Risuteganib is injected into the eye and is designed to correct ...
- Dr. Is In: Age Related Macular Degenerationon October 7, 2019 at 5:01 am
CORPUS CHRISTI, Texas — Age related macula degeneration is when the Macular of the eye is damaged as one ages, especially over the age of 60. There are two forms of it known as Dry and Wet macular ...
- LumiThera Enrolls First Patient in the U.S. Multi-Center, LIGHTSITE III Clinical Study to Treat Dry Age-Related Macular Degenerationon October 1, 2019 at 6:23 am
today announced it has begun enrolling patients in a multi-center United States clinical study in dry Age-Related Macular Degeneration (AMD) patients. In February, the company announced that the ...
- What’s the Difference Between Dry and Wet Age-Related Macular Degeneration?on September 12, 2019 at 1:00 pm
The differences between dry age-related macular degeneration and wet age-related macular degeneration can be confusing, but they’re important to know. They could mean the difference between a doctor ...
via Google News and Bing News